Dawn Svoronos - 01 Jun 2026 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Reporting relationship: Director
Issuer ticker: XENE
Reported as of: 01 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2026, 21:03:24 UTC
Prior SEC filing: 10 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Nathaniel Adams, Attorney-in-fact

Key filing fact

Dawn Svoronos filed Form 4 for Xenon Pharmaceuticals Inc. (XENE) on 03 Jun 2026.

Key facts

This page summarizes Dawn Svoronos's Form 4 filing for Xenon Pharmaceuticals Inc. (XENE).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 03 Jun 2026, 21:03.

Change

Previous filing in this sequence was filed on 10 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001574579 Primary reporting owner

Svoronos Dawn

Relationship: Director
Address: 3650 GILMORE WAY, BURNABY, BRITISH COLUMBIA, CANADA
Signature: /s/ Nathaniel Adams, Attorney-in-fact
Signature date: 03 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XENE transaction

Common Shares

Options Exercise

Transaction value
Shares: +2,645
Change %: +11%
Price
Shares after: 27,645
Date: 01 Jun 2026
Ownership: Direct
Footnotes: F1

XENE transaction

Common Shares

Tax liability

Transaction value
Shares: -1,416
Change %: -5.1%
Price: $53.41^*
Shares after: 26,229
Date: 01 Jun 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XENE transaction Derivative

Restricted Share Units

Options Exercise

Transaction value
Shares: -2,645
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 Jun 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 2,645
Exercise price
Footnotes: F1

XENE transaction Derivative

Share Option (Right to Buy)

Award

Transaction value
Shares: +10,507
Change %
Price: $0.000000^*
Shares after: 10,507
Date: 03 Jun 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 10,507
Exercise price: $53.46
Footnotes: F4

XENE transaction Derivative

Restricted Share Units

Award

Transaction value
Shares: +1,593
Change %
Price: $0.000000^*
Shares after: 1,593
Date: 03 Jun 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 1,593
Exercise price: $0.000000
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

Footnote F2

Represents the number of Common Shares withheld by the issuer to satisfy income tax withholding and remittance obligations in connection with the net settlement of the RSUs, and does not represent a sale.

Footnote F3

Represents the closing price of Common Shares on June 1, 2026 for purposes of net settlement calculations.

Footnote F4

Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

Footnote F5

Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.